Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ovarian Cancer Pipeline Products Market Report Overview

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy.

The ovarian cancer pipeline market research report provides comprehensive information on the therapeutics under development for ovarian cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for ovarian cancer and features dormant and discontinued projects.

Ovarian Cancer Pipeline Products Market Segmentation by Targets

The key targets in the ovarian cancer pipeline products market are Tubulin, DNA, Cells Expressing Mesothelin, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Poly [ADP Ribose] Polymerase 1, Programmed Cell Death Protein 1, and CD3 among others. Tubulin is the leading target in the pipeline.

Ovarian Cancer Pipeline Products Market Analysis by Targets

Ovarian Cancer Pipeline Products Market Analysis by TargetsFor more target insights into the ovarian cancer pipeline products market, download a free report sample

Ovarian Cancer Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the ovarian cancer pipeline products market are Tubulin Inhibitor, Cytotoxic To Cells Expressing Mesothelin, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA Synthesis Inhibitor, Poly [ADP Ribose] Polymerase 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, and CD3 Agonist among others. Tubulin Inhibitor is the leading MoA in the pipeline market.

Ovarian Cancer Pipeline Products Market Analysis by Mechanisms of Action

Ovarian Cancer Pipeline Products Market Analysis by Mechanisms of ActionFor more mechanisms of action insights into the ovarian cancer pipeline products market, download a free report sample

Ovarian Cancer Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the ovarian cancer pipeline products market are intravenous, oral, subcutaneous, nasal, topical, vaginal, and sublingual among others. Intravenous is the leading RoA.

Ovarian Cancer Pipeline Products Market Analysis by Routes of Administration

Ovarian Cancer Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights into the ovarian cancer pipeline products market, download a free report sample

Ovarian Cancer Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the ovarian cancer pipeline products market are small molecules, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, gene-modified cell therapy, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense RNAi oligonucleotide, and recombinant vector vaccine among others. The small molecule is the leading molecule type.

Ovarian Cancer Pipeline Products Market Analysis by Molecule Types

Ovarian Cancer Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the ovarian cancer pipeline products market, download a free report sample

Ovarian Cancer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the ovarian cancer pipeline products market are Pfizer Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, Canget BioTekpharma LLC, Novartis AG, Prestige BioPharma Ltd, Aucentra Therapeutics Pty Ltd, Bayer AG, Boehringer Ingelheim International GmbH, and Cyclacel Pharmaceuticals Inc among others. Pfizer Inc is the leading company in the ovarian cancer pipeline products market.

Ovarian Cancer Pipeline Products Market Analysis by Companies

Ovarian Cancer Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the ovarian cancer pipeline products market, download a free report sample

Ovarian Cancer Pipeline Products Market Report Overview

Key Targets Tubulin, DNA, Cells Expressing Mesothelin, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Poly [ADP Ribose] Polymerase 1, Programmed Cell Death Protein 1, and CD3
Key Mechanisms of Action Tubulin Inhibitor, Cytotoxic to Cells Expressing Mesothelin, Cytotoxic to Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA Synthesis Inhibitor, Poly [ADP Ribose] Polymerase 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, and CD3 Agonist
Key Routes of Administration Intravenous, oral, Subcutaneous, Nasal, Topical, Vaginal, and Sublingual
Key Molecule Type Small Molecules, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Recombinant Protein, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense RNAi Oligonucleotide, and Recombinant Vector Vaccine
Leading Companies Pfizer Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, Canget BioTekpharma LLC, Novartis AG, Prestige BioPharma Ltd, Aucentra Therapeutics Pty Ltd, Bayer AG, Boehringer Ingelheim International GmbH, and Cyclacel Pharmaceuticals Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of ovarian cancer.
  • The pipeline guide reviews pipeline therapeutics for ovarian cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in ovarian cancer therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates ovarian cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for ovarian cancer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for ovarian cancer.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the ovarian cancer pipeline depth and focus on Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

2Seventy Bio Inc
4D Pharma Plc
4SC AG
A2 Biotherapeutics Inc
A28 Therapeutics Inc
Aadi Bioscience Inc
AB Pharma Ltd
AbbVie Inc
Abclon Inc
Abion Inc
ABL Bio Inc
ABM Therapeutics Inc
AC Bioscience SA
Acrotech Biopharma LLC
Actuate Therapeutics Inc
Adagene Suzhou Ltd
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
ADRx Inc
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH
Agenus Inc
AI Therapeutics Inc
Alaunos Therapeutics Inc
Alkermes Plc
Alligator Bioscience AB
Alloplex Biotherapeutics Inc
Almac Discovery Ltd
Alphamab Oncology
Alpine Immune Sciences Inc
Alteogen Inc
Ambrx Biopharma Inc
Amgen Inc
Amphivena Therapeutics Inc
Amplia Therapeutics Ltd
Angex Pharmaceutical Inc
AntiCancer Inc
Anwita Biosciences Inc
AP Biosciences Inc
Apexian Pharmaceuticals Inc
Aphios Corp
APIM Therapeutics AS
Apmonia Therapeutics SAS
Apollomics Inc
Applied Research using OMIC Sciences SL
Aprea Therapeutics Inc
Aprogen Inc
Aravive Inc
Argenx SE
Asana BioSciences LLC
Ascentage Pharma Group Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
Asieris Pharmaceuticals Co Ltd
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
AtlasMedx Inc
Atossa Therapeutics Inc
Atrin Pharmaceuticals LLC
Aucentra Therapeutics Pty Ltd
Aurealis Therapeutics AG
Aurigene Discovery Technologies Ltd
Avacta Life Sciences Ltd
Avenge Bio Inc
Avesthagen Ltd
Avicanna Inc
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BBS NanoTechnology Ltd
BeiGene Ltd
Beijing Biostar Technologies Ltd
Beijing Foreland Pharma Co Ltd
Beijing FuKangren Bio-pharm Tech Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Neoantigen Biotechnology Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bexion Pharmaceuticals LLC
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
Bio-Synectics Inc
BioAtla Inc
BioInvent International AB
Biokine Therapeutics Ltd
BioMed Valley Discoveries Inc
BioMoti Ltd
BioNTech SE
Biosion Inc
Biosplice Therapeutics Inc
Biotheus Inc
BioVaxys Technology Corp
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
BoYen Therapeutics Inc
BridGene Biosciences Inc
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Canget BioTekpharma LLC
Cardiff Oncology Inc
Carina Biotech Pty Ltd
Carisma Therapeutics Inc
CaroGen Corp
Carrick Therapeutics Ltd
Cartherics Pty Ltd
CAS-Lamvac Biotech Co Ltd
Catalent Inc
Catamaran Bio Inc
Cedilla Therapeutics
Celdara Medical LLC
Cellatoz Therapeutics Inc
Celldex Therapeutics Inc
Cellid Co Ltd
Cellis AG
Cellix Bio Pvt Ltd
Cello Therapeutics Inc
Celprogen Inc
Celtec Inc
Centrymed Pharmaceutical Inc
Centurion BioPharma Corp
CHA Biotech Co Ltd
Cheetah Cell Therapeutics Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chimerix Inc
Chineo Med Beijing Co Ltd
Chongqing Pharmaceutical Research Institute Co Ltd
Chordia Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Cible Inc
Cisen Pharmaceutical Co Ltd
Clarity Pharmaceuticals Ltd
Clayton Biotechnologies Inc
Cloaked Therapeutics LLC
Clovis Oncology Inc
CMG Pharmaceutical Co Ltd
CNS Pharmaceuticals Inc
Coastar Therapeutics LLC
Codiak BioSciences Inc
Coeptis Therapeutics Holdings Inc
CohBar Inc
Coherent Biopharma
Compugen Ltd
Context Therapeutics Inc
Cotinga Pharmaceuticals Inc
Creative Therapeutics GmbH
CSPC Pharmaceutical Group Ltd
CureLab Oncology Inc
Curis Inc
Cybrexa Inc
Cyclacel Pharmaceuticals Inc
Cynvec LLC
Cyteir Therapeutics Inc
Cytodyn Inc
CytomX Therapeutics Inc
CZ BioMed Corp
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DeepCure Inc
DEKK-TEC Inc
Delta-Fly Pharma Inc
DevaCell Inc
Disulfican Ltd
Dongkook Pharmaceutical Co Ltd
Dophen Biomed Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Duo Oncology Inc
Editas Medicine Inc
Eikonoklastes Therapeutics Inc
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Ella Therapeutics Ltd
Ellipses Pharma Ltd
Elthera AG
Elucida Oncology Inc
Enara Bio Ltd
ENB Therapeutics LLC
Enlivex Therapeutics Ltd
Epigene Therapeutics Inc
EpiThany Inc
Epizyme Inc
Epsilogen Ltd
Epygen Biotech Pvt Ltd
Essential Biotechnology LLC
Etirarx LLC
Eureka Therapeutics Inc
Evestra Inc
Exelixis Inc
ExonanoRNA LLC
Exscientia Plc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Falcon Therapeutics Inc
Fate Therapeutics Inc
Felicitex Therapeutics Inc
For-Robin Inc
Froceth
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
Gadeta BV
GAiA BioMedicine Inc
Geistlich Pharma AG
GeneCare Research Institute Co Ltd
Genekey Biotech Chengdu Co Ltd
Genelux Corp
Genentech USA Inc
Geneos Therapeutics Inc
Genesen Co Ltd
Genexine Inc
Genisphere LLC
Genmab AS
GeoVax Labs Inc
Gilead Sciences Inc
GLG Pharma SA
Glycomantra Inc
GlycoNex Inc
Glycotope GmbH
Glysantis Inc
GlyTherix Ltd
Gmax Biopharm LLC
GO Therapeutics Inc
GP Pharm SA
Green Cross LabCell Corp
Greenfire Bio LLC
Greenwich LifeSciences Inc
GSK plc
GT Biopharma Inc
Guangdong Yinzhu Pharmaceutical Technology Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Guojian Chengnuo Biotechnology Beijing Co Ltd
H-CYTE Inc
HaimBio Ltd
Hangzhou Neoantigen Therapeutics Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
HCW Biologics Inc
HDT Bio Corp
HebeCell Corp
HEC Pharma Co Ltd
Helixmith Co Ltd
Henan Topfond Pharmaceutical TCM Co Ltd
Hinova Pharmaceuticals Co Ltd
Horizon Therapeutics Plc
HRAIN Biotechnology Co Ltd
Huadong Medicine Co Ltd
Hubei Soundny Bio-Tech Co Ltd
Hummingbird Bioscience Pte Ltd
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
I-Mab
I-Mab Biopharma Co Ltd
Ideaya Biosciences Inc
Idera Pharmaceuticals Inc
Idience Co Ltd
IGF Oncology LLC
Ikena Oncology Inc
Iksuda Therapeutics Ltd
ImaginAb Inc
ImCheck Therapeutics SAS
Immatics NV
IMMD Inc
Immix BioPharma Inc
Immune Biosolutions Inc
Immune Modulatory Therapies LLC
Immune Pharmaceuticals Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitor Inc
ImmunityBio Inc
Immuno Cure BioTech Ltd
Immunocore Holdings Plc
ImmunoGen Inc
ImmunSYS Inc
Immvira Co Ltd
IMPACT Therapeutics Inc
Implicyte Inc
Imugene Ltd
Imunon Inc
IMV Inc
Imvax Inc
Incyclix Bio LLC
Incyte Corp
Indi Molecular Inc
Infinity Pharmaceuticals Inc
Inmune Bio Inc
Innate Pharma SA
InnoMedica Holding AG
Innovative Cellular Therapeutics Co Ltd
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Intensity Therapeutics Inc
Inventiva SA
Invion Ltd
InxMed (Beijing) Co Ltd
IO Biotech Inc
Ionic Pharmaceuticals LLC
Iovance Biotherapeutics Inc
ITM Isotope Technologies Munich SE
Jacobio Pharmaceuticals Group Co Ltd
January Therapeutics Inc
JenKem Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Jivana Biotechnology Inc
JN Biosciences LLC
Johnson & Johnson
Jounce Therapeutics Inc
JSK Therapeutics Inc
Kalos Therapeutics Inc
Karyopharm Therapeutics Inc
Kenjockety Biotechnology Inc
KeViRX Inc
Kiadis Pharma NV
Kineta Inc
Kinnate Biopharma Inc
Kintara Therapeutics Inc
Kirilys Therapeutics Inc
Kong's Pharmaceutical
Kringle Pharma Inc
KSQ Therapeutics Inc
Kyowa Kirin Co Ltd
L&L Biopharma Co Ltd
L.E.A.F. Pharmaceuticals LLC
Laekna Therapeutics Shanghai Co Ltd
Laevoroc Oncology AG
LaNova Medicines Ltd
Lantern Pharma Inc
Lassogen Inc
LATITUDE Pharmaceuticals Inc
Le Sun Pharmaceuticals Ltd
Legend Biotech Corp
LegoChem Biosciences Inc
Leucid Bio Ltd
Lin Bioscience Inc
Lipac Oncology LLC
Lipocure Ltd
Lipomedics Ltd
LipoSeuticals Inc
Livzon Pharmaceutical Group Co Ltd
Lixte Biotechnology Holdings Inc
Luminus Biosciences Inc
Lycera Corp
Lyvgen Biopharma Ltd
Machavert Pharmaceuticals LLC
MacroGenics Inc
MAIA Biotechnology Inc
Marker Therapeutics Inc
MaxiVAX SA
MedAnnex Ltd
MedGene Therapeutics Inc
MediaPharma SRL
Medicenna Therapeutics Corp
MediciNova Inc
MediGene AG
Meditope Biosciences Inc
Medolife Rx Inc
Mendus AB
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
MicroQuin Ltd
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Minerva Biotechnologies Corp
Mirati Therapeutics Inc
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech Inc
Monopar Therapeutics Inc
Monte Rosa Therapeutics Inc
MorphoSys AG
Mosaic ImmunoEngineering Inc
Multitude therapeutics Inc
Mundipharma EDO GmbH
Myeloid Therapeutics Inc
N1 Life Inc
Nammi Therapeutics Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing Blue Shield Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing KAEDI Biotech Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Nanogenics Ltd
NanoVation Therapeutics Inc
Nemucore Medical Innovations Inc
Neomics Pharmaceuticals LLC
Neosome Life Sciences LLC
NewBio Therapeutics Inc
NextCure Inc
NGM Biopharmaceuticals Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Northlake International LLC
NovaRock Biotherapeutics Inc
Novartis AG
Noviga Research AB
Novita Pharmaceuticals Inc
NUAgo Therapeutics Inc
Nuvalent Inc
Nuvation Bio Inc
Nuvectis Pharma Inc
OBiO Technology (Shanghai) Corp Ltd
Ocellaris Pharma Inc
Omeros Corp
Omideon Ltd
OmniCyte Ltd
Ona Therapeutics SL
OncoC4 Inc
Oncodesign SA
Oncolyze Inc
Oncomatryx Biopharma SL
Onconic Therapeutics Co Ltd
OncoOne Research & Development GmbH
OncoQuest Inc
OncoResponse Inc
OncoTartis Inc
OncoTherapy Science Inc
Oncoxx Biotech Srl
OneThree Biotech Inc
ONK Therapeutics Ltd
Ono Pharmaceutical Co Ltd
Onxeo SA
OPKO Health Inc
Opna Bio SA
Orano Med LLC
ORCA Therapeutics BV
Oregon Therapeutics
Orgenesis Inc
Orpheus Therapeutics Inc
OS Therapies LLC
Oxford BioTherapeutics Ltd
Oxford Vacmedix UK Ltd
Pact Pharma Inc
Pai Life Sciences Inc
Palisades Therapeutics
Palleon Pharmaceuticals Inc
Pamdeca LLC
Pan Cancer T BV
Panbela Therapeutics Inc
Pantarhei Oncology BV
Papyrus Therapeutics Inc
Parasol Biotech Co Ltd
Patrys Ltd
PDS Biotechnology Corp
PENAO Pty Ltd
PEP-Therapy SAS
PepVax Inc
Perseus Proteomics Inc
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
PharmAust Ltd
Pharos iBio Co Ltd
Pheast Therapeutics Inc
Phi Pharma SA
Phio Pharmaceuticals Corp
pHion Therapeutics Ltd
PI Therapeutics Ltd
Pinotbio Inc
Pionyr Immunotherapeutics Inc
Plus Therapeutics Inc
Portage Biotech Inc
Poseida Therapeutics Inc
Precigen Inc
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
Prestige BioPharma Ltd
Primetime Life Sciences LLC
PRISM Pharma Co Ltd
Processa Pharmaceuticals Inc
Proen Therapeutics Co Ltd
ProLynx LLC
Promontory Therapeutics Inc
Propanc Biopharma Inc
Protheragen Inc
Provectus Biopharmaceuticals Inc
Providence Therapeutics Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Purple Biotech Ltd
Pyxis Oncology Inc
Qilu Pharmaceutical Co Ltd
Qu Biologics Inc
Quadriga BioSciences Inc
Que Oncology Inc
QureBio Ltd
Qwixel Therapeutics LLC
R-Pharm
Race Oncology Ltd
Radiopharm Theranostics Ltd
Rain Therapeutics Inc
Recordati SpA
Recursion Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Relay Therapeutics Inc
RemeGen Co Ltd
Repare Therapeutics Inc
Rescue Therapeutics Inc
Reven Holdings Inc
Revere Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Roivant Sciences Inc
RS Oncology LLC
RS Research
Rubicon Biotechnology Inc
Sagimet Biosciences Inc
Salarius Pharmaceuticals Inc
Sanofi
Sapvax LLC
Sathgen Biotech
Sator Therapeutics LLC
Scancell Holdings Plc
Scandion Oncology AS
Scholar Rock Inc
Seagen Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Sequoia Vaccines Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Affinity Biomedical Technology Co Ltd
Shanghai Cell Therapy Group Co
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Huilun Life Science & Technology Co Ltd
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shanghai Miracogen Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Yihao Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanghai Yuansong Biotechnology Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shorla Pharma Ltd
Sichuan Kangdesai Medical Technology Co Ltd
SideROS
Sihuan Pharmaceutical Holdings Group Ltd
Simcha Therapeutics Inc
siRNAgen Therapeutics Corp
SL Bigen Co Ltd
SN BioScience
Sonoval LLC
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
SOTIO Biotech AS
Sphaera Pharma Pte Ltd
Splash Pharmaceuticals Inc
SpringWorks Therapeutics Inc
Starpharma Holdings Ltd
Statera Biopharma Inc
Stingthera Inc
Sumitomo Dainippon Pharma Oncology, Inc
Sun Pharma Advanced Research Company Ltd
Sunshine Biopharma Inc
Suntec Medical (Taiwan) Inc
SuperTrans Medical Ltd
Supratek Pharma Inc
Susavion Biosciences Inc
Sutro Biopharma Inc
Suzhou Immunofoco Biotechnology Co Ltd
Suzhou Innovative Biomaterials & Pharmaceutics Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Suzhou Neupharma Co Ltd
Suzhou Stainwei Biotech Inc
Suzhou Zerun New Drug Research and Development Co Ltd
Synergys Biotherapeutics Inc
Synthekine Inc
Syros Pharmaceuticals Inc
Systimmune Inc
T-Cure Bioscience Inc
Tactiva Therapeutics LLC
TAE Life Sciences LLC
Tagworks Pharmaceuticals BV
Taiho Pharmaceutical Co Ltd
Tailored Therapeutics LLC
Takeda Pharmaceutical Co Ltd
Takis Srl
Tango Therapeutics Inc
Targovax ASA
Tarveda Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
TCR Cure Biopharma Technology Co Ltd
TCR2 Therapeutics Inc
Tempest Therapeutics Inc
Temple Therapeutics BV
Teon Therapeutics Inc
Tetranov International Inc
Theolytics Ltd
Theranano LLC
TheraTarget Inc
Theratechnologies Inc
Thetis Pharmaceuticals LLC
TILT Biotherapeutics Ltd
Tmunity Therapeutics Inc
ToolGen Inc
TORL Biotherapeutics LLC
TOT Biopharm Co Ltd
TRACON Pharmaceuticals Inc
Tradewind BioScience Inc
Transcenta Holding Ltd
Transgene SA
TransGenex Nanobiotech Inc
Treos Bio Ltd
Triumvira Immunologics Inc
TVAX Biomedical Inc
TYK Medicines Inc
Tyme Inc
UBI Pharma Inc
UbiVac Inc
United Immunity Co Ltd
Up Therapeutics Inc
UTC Therapeutics Inc
UWELL Biopharma Inc
VacV Biotherapeutics Ltd
ValiRx Plc
Vaxil Bio Therapeutics Ltd
Vectorite Biomedical Inc
Venus Remedies Ltd
Verastem Inc
Verismo Therapeutics
Vertex Pharmaceuticals Inc
Veru Inc
Vincerx Pharma Inc
Vivesto AB
VM Discovery Inc
Voltron Therapeutics Inc
Wuhan YZY Biopharma Co Ltd
XEME BioPharma Inc
Xencor Inc
Xiangxue Life Sciences
Xilio Therapeutics Inc
XinThera Inc
XuanZhu Biological Technology Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Yooyoung Pharm Co Ltd
Zenith Epigenetics Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Landun Pharmaceutical Co Ltd
Zhuhai Beihai Biotech Co Ltd
Zhuhai GRIT biotechnology Inc
ZielBio Inc
Zy Therapeutics Inc
Zylem Biosciences Inc
Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ovarian Cancer – Overview

Ovarian Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ovarian Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ovarian Cancer – Companies Involved in Therapeutics Development

Ovarian Cancer – Drug Profiles

Ovarian Cancer – Dormant Projects

Ovarian Cancer – Discontinued Products

Ovarian Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Ovarian Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ovarian Cancer – Dormant Projects, 2022

Ovarian Cancer – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Ovarian Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.